Stay updated with breaking news from Asserted Claims. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Jury Upholds Validity of Asserted Claims of the Patent, Finds Willful Infringement and Issues Past Damages Award of $41.82 Million - - Seagen to Req
Our review found just four cases where a jury addressed some aspect of Section 101, all from the Eastern District of Texas….
To embed, copy and paste the code into your website or blog: On January 14, 2020, the Federal Court released a decision by Phelan J. in patent infringement actions pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations ( PMNOC Regulations) relating to the drug abiraterone acetate (Janssen’s ZYTIGA). The Court found Canadian Patent No. 2,661,422 (the 422 patent) invalid on the basis of obviousness and dismissed the Plaintiffs’ actions against Apotex, Dr. Reddy’s Laboratories, and Pharmascience: Janssen Inc v Apotex Inc, 2021 FC 7. As reported earlier...
On January 14, 2021, the Federal Court issued a decision ( Janssen Inc. et al v. Apotex Inc. et al, 2021 FC 7) in the consolidated infringement action brought under s. 6(1) of the Patented Medicine (Notice of Compliance) (PM(NOC)) Regulations by Janssen against Apotex, Dr. Reddy's Laboratory, and Pharmascience. In this decision, the Court invalidated the asserted claims of Janssen's Canadian Patent 2,661,422 (the 422 Patent), which claimed the combined use of the two active ingredients found in Janssen's brand name drug ZYTIGA, abiraterone acetate and prednisone, in the treatment of prostate ...